Medicine for Ibbs article Posted by The Guardian on Tuesday, January 13, 2019 12:02:56The first patient to receive an ibuprofen injection is Dr David Halliday, an orthopaedic surgeon in Melbourne.
“We’ve had a couple of patients who have had some pretty severe cases of upper limb pain and we’ve just been really impressed by their ability to walk around, to sit up and to stand up,” he told 7.30.
“It’s been really encouraging, and we’re hoping that will continue for a few more weeks.”
Halliday is currently working on the development of an ibex-based ibupropfen, but said the drug has already seen its fair share of criticism.
“I think it’s going to be a lot more of an open discussion around the fact that this drug works, and that there’s no reason why it can’t work,” he said.
“There’s not going to come a time where it’s not safe, and it won’t come a point where it is.”
But at the same time, I think it is important for patients to know that they are not alone and that other doctors and pharmacists are taking it seriously.””
There are so many different types of pain management that you can look to.
“Dr Halliday said it was difficult to predict how quickly the drug would reach market, but that he expected it to be available within a few years.”
One of the biggest things that people are going to have to be patient about is the cost, the cost of the drug, and then also the time it takes for the product to get there,” he explained.”
Once it’s available, we’re going to see an enormous increase in patients using it.
“The drug has been approved by the Australian Medicines and Pharmaceuticals Commission (AMPC) for use in patients with mild or moderate to severe upper limb spondylolisthesis, which is a condition in which the muscles around the lower leg are fused together.
The AMPC has also issued a provisional safety declaration for the drug.”
If you’re looking for a treatment that’s going be safe, it’s very easy to get it,” Dr Halliday explained.”[Ibuprofens] works because it has an extremely low risk of side effects, which are relatively mild and very manageable.””
We think it might be worth the price and it’s a very low cost.
“Halladay said it could take up to five years to fully commercialise the drug and was keen to continue working with the AMPC.”
As a medical device company, we have to have the right safety protocols in place,” he noted.”
What we’re looking at is doing this in a controlled environment so that we can make sure it’s safe for the patient.
“The fact that the AMSC has been in touch and they’re very encouraging has really helped us.”
“I really hope that the company is going to move quickly, as quickly as possible, so we can get this medicine on the market.”